Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.
What else is happening in Research?
Research
Update: JPMorgan Upgrades Tesla to Neutral From Underweight as 'Vertical Integration & Tech Efficacy Unmatched', $475 Price Target
(Updated to include JPMorgan's commentary)JPMorgan upgraded Tesla (TSLA) to neutral from underweight, noting the company's unmatched vertical integration is a "unique advantage."The EV maker is at the forefront of physical AI, entering uncharted TAMs, and its strong execution will be vital to accelerating adoption and increasing the size of these TAMs themselves, analysts led by Rajat Gupta wrote in a Friday note.Tesla has an average rating of overweight and mean price target of $400.22, according to analysts polled by FactSet.Price: $406.60, Change: $-11.85, Percent Change: -2.83%
$TSLA
Research
JPMorgan Upgrades Tesla to Neutral From Underweight, $475 Price Target
Tesla (TSLA) has an average rating of overweight and mean price target of $400.22, according to analysts polled by FactSet.Price: $413.97, Change: $-4.48, Percent Change: -1.07%
$TSLA
Research
Morgan Stanley Upgrades Inditex to Overweight, Boosts PT
Morgan Stanley on Friday upgraded Spanish clothing retailer Industria de Diseño Textil (ITX.MC), d/b/a Inditex, to overweight from equal weight and raised its price target to 62 euros from 52.50 euros.
$ITX.MC